[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

NO20000257L - Modifisert immunogent pneumolysin, sammensetninger omfattende dette samt anvendelse derav som vaksine - Google Patents

Modifisert immunogent pneumolysin, sammensetninger omfattende dette samt anvendelse derav som vaksine

Info

Publication number
NO20000257L
NO20000257L NO20000257A NO20000257A NO20000257L NO 20000257 L NO20000257 L NO 20000257L NO 20000257 A NO20000257 A NO 20000257A NO 20000257 A NO20000257 A NO 20000257A NO 20000257 L NO20000257 L NO 20000257L
Authority
NO
Norway
Prior art keywords
vaccine
compositions
modified immunogenic
pneumolysin
immunogenic pneumolysin
Prior art date
Application number
NO20000257A
Other languages
English (en)
Norwegian (no)
Other versions
NO20000257D0 (no
Inventor
Joseph Y Tai
Conceicao Minetti
Francis Michon
Jeffrey K Pullen
Maryellen Polvino-Bodnar
Shu-Mei Liang
Original Assignee
Baxter Healthcare Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Healthcare Sa filed Critical Baxter Healthcare Sa
Publication of NO20000257D0 publication Critical patent/NO20000257D0/no
Publication of NO20000257L publication Critical patent/NO20000257L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C07K14/3156—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci from Streptococcus pneumoniae (Pneumococcus)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/831—Drug, bio-affecting and body treating compositions involving capsular polysaccharide of bacterium, e.g. polyribosyl ribitol phosphate
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/825—Bacteria

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
NO20000257A 1997-07-21 2000-01-19 Modifisert immunogent pneumolysin, sammensetninger omfattende dette samt anvendelse derav som vaksine NO20000257L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5330697P 1997-07-21 1997-07-21
US7345698P 1998-02-02 1998-02-02
PCT/US1998/014716 WO1999003884A2 (fr) 1997-07-21 1998-07-21 Compositions de pneumolysine immunogene modifiee utiles en tant que vaccins

Publications (2)

Publication Number Publication Date
NO20000257D0 NO20000257D0 (no) 2000-01-19
NO20000257L true NO20000257L (no) 2000-03-21

Family

ID=26731692

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20000257A NO20000257L (no) 1997-07-21 2000-01-19 Modifisert immunogent pneumolysin, sammensetninger omfattende dette samt anvendelse derav som vaksine

Country Status (9)

Country Link
US (2) US6764686B2 (fr)
EP (1) EP0998557A2 (fr)
JP (1) JP2001510031A (fr)
KR (1) KR100619350B1 (fr)
AU (1) AU740956B2 (fr)
CA (1) CA2297374A1 (fr)
HU (1) HUP0002475A3 (fr)
NO (1) NO20000257L (fr)
WO (1) WO1999003884A2 (fr)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8791237B2 (en) 1994-11-08 2014-07-29 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of non-hodgkins lymphoma
BR0009163A (pt) 1999-03-19 2001-12-26 Smithkline Beecham Biolog Vacina
GB9906437D0 (en) * 1999-03-19 1999-05-12 Smithkline Beecham Biolog Vaccine
GB9918319D0 (en) 1999-08-03 1999-10-06 Smithkline Beecham Biolog Vaccine composition
GB0022742D0 (en) * 2000-09-15 2000-11-01 Smithkline Beecham Biolog Vaccine
US8771702B2 (en) 2001-03-26 2014-07-08 The Trustees Of The University Of Pennsylvania Non-hemolytic LLO fusion proteins and methods of utilizing same
GB0109297D0 (en) 2001-04-12 2001-05-30 Glaxosmithkline Biolog Sa Vaccine
EP2258386A3 (fr) 2002-08-02 2011-11-02 GlaxoSmithKline Biologicals S.A. Composition vaccinale contre Neisseria
AU2003278166B2 (en) 2002-11-01 2009-01-29 Glaxosmithkline Biologicals S.A. Immunogenic composition
ES2451620T3 (es) 2002-11-07 2014-03-28 Synergy America, Inc. Composiciones y métodos destinados a tratar o prevenir la infección neumocócica
RU2340627C2 (ru) 2003-03-13 2008-12-10 ГлаксоСмитКлайн Байолоджикалз с.а. Способ очистки бактериального цитолизина
CA2539715C (fr) 2003-10-02 2015-02-24 Glaxosmithkline Biologicals S.A. Antigenes pertussis et leur utilisation dans la vaccination
US20120027841A1 (en) 2004-01-07 2012-02-02 Biomedical Research Models, Inc. Novel mucosal vaccination approach for herpes simplex virus type-2
EP1713917A4 (fr) * 2004-02-13 2009-06-17 Sanofi Pasteur Ltd Derives de pneumolysine
GB0410220D0 (en) * 2004-05-07 2004-06-09 Kirkham Lea Ann Mutant pneumolysin proteins
WO2005108419A1 (fr) * 2004-05-07 2005-11-17 Lea-Ann Kirkham Proteines mutantes de cytolysine liant le cholesterol
KR20070085236A (ko) * 2004-08-23 2007-08-27 메다렉스, 인코포레이티드 뉴몰리신에 대한 결합원
GB0421083D0 (en) * 2004-09-22 2004-10-27 Glaxosmithkline Biolog Sa Purification process
GB0505996D0 (en) 2005-03-23 2005-04-27 Glaxosmithkline Biolog Sa Fermentation process
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
JP5579387B2 (ja) 2005-12-22 2014-08-27 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 肺炎連鎖球菌莢膜多糖類コンジュゲートを含むワクチン
US8617565B2 (en) 2006-01-17 2013-12-31 Arne Forsgren et al. Surface exposed Haemophilus influenzae protein (protein E; pE)
US9370557B2 (en) * 2006-06-15 2016-06-21 The University Court Of The University Of Glasgow Adjuvant compounds
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
ES2675915T3 (es) 2006-09-26 2018-07-13 Infectious Disease Research Institute Composición de vacuna que contiene un adyuvante sintético
SI2086582T1 (sl) 2006-10-12 2013-02-28 Glaxosmithkline Biologicals S.A. Cepivo, ki obsega emulzijo olja v vodi kot adjuvans
MX2009003325A (es) 2006-10-12 2009-04-09 Glaxosmithkline Biolog Sa Vacuna que comprende un adyuvante de emulsion de aceite en agua.
US9717788B2 (en) 2007-03-02 2017-08-01 Glaxosmithkline Biologicals Sa Method of inducing an immune response against HIV employing HIV immunogens, adenoviral vectors encoding said immunogens, and adjuvant
CA2896131C (fr) 2007-03-02 2020-04-07 Glaxosmithkline Biologicals S.A. Nouveau procede et nouvelles compositions
BRPI0810211A2 (pt) * 2007-04-13 2014-10-21 Univ Oklahoma Citolisina dependente de colesterol mutante purficada, composição, vacina, método para vacinar um paciente, anticorpo monoclonal, ácido nucléico, e, célula hospedeira.
EP2687228B1 (fr) 2007-06-26 2017-07-19 GlaxoSmithKline Biologicals S.A. Vaccin contenant des conjugues de polysaccharide capsulaire de streptococcus pneumoniae
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
EP2271360B1 (fr) 2008-04-16 2015-09-23 GlaxoSmithKline Biologicals S.A. Vaccin
WO2009143413A1 (fr) * 2008-05-22 2009-11-26 Children'smedical Center Corporation Conjugué immunogène synergique protéine de fusion-polysaccharide
GB0815872D0 (en) 2008-09-01 2008-10-08 Pasteur Institut Novel method and compositions
BRPI0923649A2 (pt) 2008-12-24 2016-01-19 Netherlands Vaccine Inst polipeptídeos de pneumolisina (ply) de streptococcus pneumoniae modificados.
RU2555757C2 (ru) 2009-03-24 2015-07-10 Новартис Аг Комбинации менингококкового фактор н-связывающего белка и пневмококковых сахаридных конъюгатов
HUE031051T2 (en) 2009-06-05 2017-06-28 Infectious Disease Res Inst Synthetic glycopyranosyl lipid adjuvant and vaccine compositions containing it
KR20120081587A (ko) 2009-09-10 2012-07-19 노파르티스 아게 기도 질병에 대한 조합 백신
GB201003924D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Immunogenic composition
EP2544714A1 (fr) 2010-03-10 2013-01-16 GlaxoSmithKline Biologicals S.A. Composition de vaccin
EP2550289A4 (fr) * 2010-03-12 2013-11-27 Childrens Medical Center Nouveaux immunogènes et procédés pour la découverte et le dépistage de ceux-ci
EA024701B1 (ru) 2010-04-13 2016-10-31 Селлдекс Терапьютикс Инк. Антитела, связывающие cd27 человека, и их применение
GB201015132D0 (en) 2010-09-10 2010-10-27 Univ Bristol Vaccine composition
WO2012072769A1 (fr) 2010-12-01 2012-06-07 Novartis Ag Epitopes rrgb de pneumocoque et combinaisons de variantes
AU2011336366B2 (en) 2010-12-03 2016-05-12 Sanofi Pasteur Limited Composition for immunization against Streptococcus pneumoniae
GB201022007D0 (en) 2010-12-24 2011-02-02 Imp Innovations Ltd DNA-sensor
JP6054942B2 (ja) 2011-04-08 2016-12-27 イミューン デザイン コーポレイション 免疫原性組成物、ならびに体液性および細胞性免疫応答を誘発するための該組成物の使用方法
EP2709658A1 (fr) 2011-05-17 2014-03-26 GlaxoSmithKline Biologicals SA Vaccin contre streptococcus pneumoniae
WO2013020090A2 (fr) * 2011-08-04 2013-02-07 The Regents Of The University Of California Glycopolypeptides dépourvus de glcnac streptococcique, glucides de paroi cellulaire, vaccins streptococciques et procédés pour les fabriquer et les utiliser
EP2811981B1 (fr) 2012-02-07 2019-05-08 Infectious Disease Research Institute Formulations d'adjuvant amélioré comprenant des agonistes de tlr4 et leurs procédés d'utilisation
US20150132339A1 (en) 2012-03-07 2015-05-14 Novartis Ag Adjuvanted formulations of streptococcus pneumoniae antigens
US9555099B2 (en) 2012-05-16 2017-01-31 Immune Design Corp. Vaccines for HSV-2
US20140193451A1 (en) * 2012-10-17 2014-07-10 Glaxosmithkline Biologicals Sa Immunogenic composition
CA2897398A1 (fr) 2013-01-07 2014-07-10 Biomedical Research Models, Inc. Utilisation de vaccins pour le traitement d'infections par l'herpes simplex virus type 2
EP4272750A3 (fr) 2013-02-07 2024-01-24 Children's Medical Center, Corp. Antigènes de protéine qui confèrent une protection contre une colonisation et/ou une maladie pneumococcique
EP3711768A1 (fr) 2013-04-18 2020-09-23 Immune Design Corp. Monothérapie de gla destinée à être utilisée dans le traitement du cancer
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
EP3915579A1 (fr) 2013-12-31 2021-12-01 Infectious Disease Research Institute Formulations de vaccin à flacon unique
US9107906B1 (en) 2014-10-28 2015-08-18 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
AU2015349787B2 (en) 2014-11-21 2021-07-29 The Board Of Regents Of The University Of Oklahoma Pneumolysin mutants and methods of use thereof
US20180044429A1 (en) 2015-03-09 2018-02-15 Celldex Therapeutics, Inc. Cd27 agonists
GB201518684D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Vaccine
WO2017176076A1 (fr) 2016-04-06 2017-10-12 Ewha University - Industry Collaboration Foundation Peptide ayant la capacité de pénétrer une membrane cellulaire
SG11201808821WA (en) 2016-04-18 2018-11-29 Celldex Therapeutics Inc Agonistic antibodies that bind human cd40 and uses thereof
WO2017200957A1 (fr) 2016-05-16 2017-11-23 Infectious Disease Research Institute Liposomes pégylés et procédés d'utilisation
WO2017200852A1 (fr) 2016-05-16 2017-11-23 Infectious Disease Research Institute Formulation contenant un agoniste de tlr et procédés d'utilisation
WO2017210364A1 (fr) 2016-06-01 2017-12-07 Infectious Disease Research Institute Nanoparticules d'alun contenant un agent d'encollage
GB201610599D0 (en) 2016-06-17 2016-08-03 Glaxosmithkline Biologicals Sa Immunogenic Composition
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
WO2018175783A1 (fr) * 2017-03-22 2018-09-27 Modernatx, Inc. Vaccins antibactériens à arn
KR20240096685A (ko) 2017-06-15 2024-06-26 액세스 투 어드밴스드 헬스 인스티튜트 나노구조 지질 담체 및 안정적인 에멀션 그리고 이들의 용도
JP7339942B2 (ja) 2017-09-08 2023-09-06 アクセス ツー アドバンスト ヘルス インスティチュート サポニンを含むリポソーム製剤および使用方法
US20210198374A1 (en) 2018-04-17 2021-07-01 Celldex Therapeutics, Inc. Anti-cd27 and anti-pd-l1 antibodies and bispecific constructs
TW202019470A (zh) 2018-09-12 2020-06-01 美商艾芬尼維克斯公司 多價肺炎球菌疫苗
WO2020123444A1 (fr) 2018-12-11 2020-06-18 Celldex Therapeutics, Inc. Procédés d'utilisation d'anticorps cd27 en tant que traitement de conditionnement pour une thérapie cellulaire adoptive
WO2020120569A2 (fr) 2018-12-12 2020-06-18 Glaxosmithkline Biologicals Sa Protéines porteuses modifiées pour glycosylation à liaison o
JP2022532944A (ja) 2019-05-25 2022-07-20 アクセス ツー アドバンスト ヘルス インスティチュート アジュバントワクチンエマルジョンを噴霧乾燥するための組成物および方法
US20230310323A1 (en) 2020-09-04 2023-10-05 Access To Advanced Health Institute Co-lyophilized rna and nanostructured lipid carrier
AU2022253269A1 (en) 2021-04-09 2023-11-23 Celldex Therapeutics, Inc. Antibodies against ilt4, bispecific anti-ilt4/pd-l1 antibody and uses thereof
KR20240099160A (ko) 2021-09-09 2024-06-28 아피니백스, 인크. 다가 폐렴구균 백신
WO2023077521A1 (fr) 2021-11-08 2023-05-11 Celldex Therapeutics, Inc Constructions bispécifiques anti-ilt4 et anti-pd-1
WO2024052882A1 (fr) 2022-09-09 2024-03-14 Access To Advanced Health Institute Composition de vaccin immunogène incorporant une saponine

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990006951A1 (fr) * 1988-12-16 1990-06-28 De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur Mutants de pneumolysine et vaccins contre le pneumocoque obtenus a partir de tels mutants
CA2059692C (fr) 1991-01-28 2004-11-16 Peter J. Kniskern Vaccin conjugue de polysaccharide contre les pneumocoques
EP0687688A1 (fr) 1993-12-17 1995-12-20 Universidad De Oviedo Anticorps contre la pneumolysine, et leurs applications
US5565204A (en) 1994-08-24 1996-10-15 American Cyanamid Company Pneumococcal polysaccharide-recombinant pneumolysin conjugate vaccines for immunization against pneumococcal infections
US6019982A (en) * 1994-08-26 2000-02-01 The Administrators Of The Tulane Educational Fund Mutant enterotoxin effective as a non-toxic oral adjuvant
CA2262748A1 (fr) * 1996-08-12 1998-02-19 Board Of Regents, The University Of Texas System Definition d'epitopes de la proteine copb de membrane externe de moraxella catarrhalis

Also Published As

Publication number Publication date
HUP0002475A3 (en) 2002-01-28
CA2297374A1 (fr) 1999-01-28
HUP0002475A2 (hu) 2000-10-28
NO20000257D0 (no) 2000-01-19
KR20010022271A (ko) 2001-03-15
AU8407898A (en) 1999-02-10
KR100619350B1 (ko) 2006-09-05
EP0998557A2 (fr) 2000-05-10
WO1999003884A2 (fr) 1999-01-28
JP2001510031A (ja) 2001-07-31
US20050070695A1 (en) 2005-03-31
WO1999003884A3 (fr) 1999-04-08
US6764686B2 (en) 2004-07-20
AU740956B2 (en) 2001-11-15
US20010014332A1 (en) 2001-08-16

Similar Documents

Publication Publication Date Title
NO20000257L (no) Modifisert immunogent pneumolysin, sammensetninger omfattende dette samt anvendelse derav som vaksine
DZ2462A1 (fr) Vaccin antigrippal.
NO20032187D0 (no) Heterocyklylalkylpiperidinderivater, deres fremstilling samt preparater inneholdende forbindelsene
NO20003303L (no) Vaksine
NO984147D0 (no) Sammensetninger som inneholder kopolymerer som tykningsmidler
DK0789025T3 (da) Substituerede oxazolidinoner samt deres anvendelse som antibakterielle lægemidler
DE69838405D1 (de) Mikrostrukturierte, kosmetisch verträgliche Zusamensetzungen
NO20004758D0 (no) Vaksinesammensetning
ATE490327T1 (de) Impfstoffzusammensetzung
NO20004487L (no) Kombinerte vaksinesammensetninger
NO991815L (no) Oksadiazoler, fremgangsmÕter for deres fremstilling og deres anvendelse som medikamenter
NO996133D0 (no) Olje-i-vann-vaksinesammensetninger
NO20014325L (no) Vaksine
NO992102L (no) Peptidblanding, samt farmasøytisk sammensetning og kreftvaksine som innbefatter peptidblandingen
NO20006191D0 (no) Vaksine
MXPA02001891A (es) Una composicion de vacuna y metodo para utilizacion de la misma.
DZ2283A1 (fr) Composition de vaccin.
NO20030296L (no) Heparinavledede polysakkaridblandinger, deres fremstilling samt farmasöytiske preparater inneholdende blandingene
NO20020763D0 (no) Vaksine
NO20016247L (no) Streptograminderivater, deres fremstilling samt preparater inneholdende derivatene
IS5694A (is) Bóluefni
IS2797B (is) Bóluefni gegn ISA-veiru
ZA984696B (en) Vaccine compositions V.
NO20020404L (no) Streptograminderivater, deres fremstilling samt preparater inneholdende derivatene
DK1194450T3 (da) Inaktiveret vaccine imod felin calicivirose

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application